NEW YORK – Advanced Genomics APAC and CancerFree Biotech on Friday announced a memorandum of understanding to create a partnership focused on creating personalized treatment plans for cancer patients using next-generation sequencing and in vitro drug testing.
The collaboration will utilize Advanced Genomics' GALEAS Tumor platform, which combines comprehensive genomic profiling of different biomarkers and different cancer types into a single workflow. The firm said its platform detects cancer-related mutations across 519 key genes. The partners also will leverage CancerFree Biotech's ability to cultivate patient-derived cancer cells for drug response testing.
CancerFree Biotech's technology isolates circulating tumor cells from patients to create organoid models for drug response testing. The firm says its platform can create models for more than 134 solid tumor types from patient blood samples.
The partners aim to collect hundreds of patient samples in the first year to develop personalized treatment protocols for cancer patients in Taiwan. Advanced Genomics will conduct the NGS testing at its laboratory.